期刊文献+

半胱氨酸蛋白酶抑制剂C与左室射血分数关系的临床研究

下载PDF
导出
摘要 目的探讨血清半胱氨酸蛋白酶抑制剂C(CysC)浓度与左室射血分数(LVEF)的相关性,从而总结出CysC在心衰中的临床意义。方法入选病例240例,均排除各种肾病及肾功能不全,按LVEF值分为2组:LVEF值大于50%的病例组和LVEF值小于50%的病例组各120例。所有病例入院第二天清晨检测CysC水平。结果LVEF值小于50%的病例组的血清CysC浓度明显高于LVEF值大于50%的病例组(P<0.01)。结论随着LVEF值的降低,血清CysC浓度明显升高,因此CysC可以作为一个评估心衰的客观指标。
出处 《实用心脑肺血管病杂志》 2007年第12期912-913,共2页 Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
  • 相关文献

参考文献7

  • 1Mussap M, Plebani M. Biochemistry and clinical role of human cystatin C.Crit Rev Clin Lab Sci,2004,41(5-6): 467-550
  • 2Mussap M, Dalla VM, Fiorefo Petal. CysC is a moire sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients [J].KidneyInt,2002, 61 (4): 1453-1461.
  • 3李海霞,吴红花,徐国宾,郭晓蕙,夏铁安.血清半胱氨酸蛋白酶抑制剂C与肌酐在评价糖尿病患者肾小球滤过功能中的比较研究[J].中华检验医学杂志,2005,28(6):602-605. 被引量:107
  • 4李晓娟.胱氨酸蛋白酶抑制剂C的临床应用[J].国外医学(临床生物化学与检验学分册),2004,25(1):6-7. 被引量:64
  • 5Singh D, Whooley MA, lx JH, et al. Association of cystatin C and estimated GFR with inflammatory biomarkers: the Heart and Soul Study. Nephrol Dial Transplant, 2007,22 (4) : 1087-92.
  • 6Koenig W, Twardella D, Brenner H, et al. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular event,s: more than simply a marker of glomerular fihration rate. Clin Chem, 2005, 51 (2):321-7.
  • 7CJoachim H, Ix, MD, Michael G, et al. Shlipak,et al.cystatin C With Mortality, Cardiovascular Events, and Incident Heart Failure Among Persons With Coronary Heart Disease . Circulation, 2007,115 : 173-179.

二级参考文献13

  • 1Andersen JK,Schmidt C,Nordin G.Serum cystatin C.determined by a rapid,automated particle-enhanced turbidimetric method,is a better marker than serum cretinine for glomerular filtration rate.Clin Chem,1994,40(10):1921-1926.
  • 2Randers E,Erlandsen EJ.Serum cystatin C as endogenous marker of the renal function-a review.ClinChem Lab Med,1999,37(4):389-395.
  • 3keevil GB,Kilpatrick ES,Nichols SP,et al.Biological variation of cystatin C:implication for the assessnent of glomerular filtration rate.Clin chem.1998,44(7):1535-1539.
  • 4Finney H,Newman DJ,Gruber W.Initial evaluatin of cystatin C measurement by particle-enhanced immunonephelometry on the Behring nephelometer systems(BNA,BN Ⅱ).Clin Chem,1997,43(6):1016-1020.
  • 5周玉红 左力 王梅.MDRD方程预测肾小球滤过率的临床应用评价[J].中华肾脏病杂志,2004,20:30-34.
  • 6Randers E, Erlandsen EJ. Serum Cystatin C as an endogenous marker of the renal function - a review. Clin Chem Lab Med , 1999,37:389-395.
  • 7Mojimintyi OA, Abdella N, George S. Evaluation of serum cystatin C and chromogranin A as markers of nephropathy in patients with type 2 diabetes mellitus. Scand J Clin Lab Invest, 2000, 60:483-489.
  • 8Oddoze C, Morange S, Portugal H, et al. Cystatin C is not more sensitive than creatinine for detecting early renal impairment in patients with diabetes. Am J Kidney Dis, 2001,38:310-316.
  • 9Dharnidharka VR,Kwon C,Stevens G. Serum Cystatin C is superior to serum creatinine as a marker of kidney function:a meta-analysis. Am J Kidney Dis, 2002,40:221-226.
  • 10Levey AS,Bosch JP,Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine:a new prediction equation. Ann Intern Med, 1999,130:461-470.

共引文献162

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部